|
Jul 7
|
Apogee Dives. But It Could Eventually Rival Sanofi's Biggest Moneymaker.
|
|
Jul 7
|
Novo and Lilly compete in India as obesity drugs demand hikes
|
|
Jul 7
|
Smith Blasts Novo, Coloplast in Danish Life Science Rebuke
|
|
Jul 7
|
Intellia Gains 29.8% in a Month: How Should You Play the Stock?
|
|
Jul 7
|
Demand for obesity drugs shoots up in India as Lilly, Novo vie for market share
|
|
Jul 7
|
GLP-1 roadblocks: Discontinuation rates soar as insurers clamp down
|
|
Jul 7
|
Better Growth Buy: Eli Lilly vs. Viking Therapeutics
|
|
Jul 6
|
2 Dividend Growth Stocks to Buy and Hold Forever
|
|
Jul 4
|
Will Novo Nordisk's Rare Disease Bets Reduce GLP-1 Reliance?
|
|
Jul 4
|
UBS Sees Strong Sales Outlook for Eli Lilly’s Zepbound and Mounjaro
|
|
Jul 4
|
Lilly and Novo Are the Kings of Weight-Loss Drugs. The Companies Coming for Their Crowns.
|
|
Jul 3
|
Novo Nordisk Ignored Internal Warnings On Wegovy Launch Preparedness: Report
|
|
Jul 3
|
Eli Lilly (LLY) Staring at Tremendous Opportunity in Alzheimer Market: RBC Capital Markets
|
|
Jul 3
|
Pfizer Trades Above 50-Day Average for a Month: Time to Buy?
|
|
Jul 3
|
Here's How Lilly's Non-Obesity Drugs are Contributing to Sales Growth
|
|
Jul 2
|
Wall Street Bulls Look Optimistic About Lilly (LLY): Should You Buy?
|
|
Jul 2
|
Will AbbVie's Acquisition Spree Aid Pipeline Growth?
|
|
Jul 2
|
Semaglutide Market Forecast Report 2025-2033 | Growth Accelerates Amid Rising Awareness, Regulatory Approvals, and Strong Pipeline Advancements
|
|
Jul 2
|
2 Growth Stocks to Buy Hand Over Fist in July
|
|
Jul 2
|
This GLP-1 Stock's Bad News Could Be a Big Win for Eli Lilly and Novo Nordisk
|